phosphodiesterase 5A

Target id: 1304

Nomenclature: phosphodiesterase 5A

Abbreviated Name: PDE5A

Family: Phosphodiesterases, 3',5'-cyclic nucleotide (PDEs)

Annotation status:  image of a grey circle Awaiting annotation/under development. Please contact us if you can help with annotation.  » Email us

   GtoImmuPdb view: OFF :     phosphodiesterase 5A has curated GtoImmuPdb data

Gene and Protein Information
Species TM AA Chromosomal Location Gene Symbol Gene Name Reference
Human - 875 4q27 PDE5A phosphodiesterase 5A
Mouse - 865 3 53.69 cM Pde5a phosphodiesterase 5A, cGMP-specific
Rat - 833 2q42 Pde5a phosphodiesterase 5A
Previous and Unofficial Names
cGMP-binding cGMP specific phosphodiesterase 5A2 | PDE5A2 | PDE5A1 | phosphodiesterase 5A, cGMP-specific
Database Links
BRENDA
CATH/Gene3D
DrugBank Target
Ensembl Gene
Entrez Gene
Human Protein Atlas
KEGG Enzyme
KEGG Gene
OMIM
SynPHARM
UniProtKB
Wikipedia
Enzyme Reaction
EC Number: 3.1.4.17
Activators (Human)
Protein kinase A, protein kinase G  [5]
Rank order of affinity (Human)
cyclic GMP > cyclic AMP

Download all structure-activity data for this target as a CSV file

Inhibitors
Key to terms and symbols View all chemical structures Click column headers to sort
Ligand Sp. Action Affinity Units Reference
compound 53 [PMID: 19631533] Hs Inhibition 10.3 pIC50 6
pIC50 10.3 (IC50 5x10-11 M) [6]
vardenafil Hs Inhibition 9.7 pIC50 3
pIC50 9.7 (IC50 2x10-10 M) [3]
T0156 Hs Inhibition 9.5 pIC50 8
pIC50 9.5 (IC50 3.16x10-10 M) [8]
PF-00489791 Hs Inhibition 9.1 pIC50 4
pIC50 9.1 (IC50 7.1x10-10 M) [4]
gisadenafil Hs Inhibition 8.9 pIC50 10
pIC50 8.9 [10]
sildenafil Hs Inhibition 8.4 – 9.0 pIC50 11,14
pIC50 8.4 – 9.0 (IC50 3.9x10-9 – 1x10-9 M) [11,14]
tadalafil Hs Inhibition 8.5 pIC50 9
pIC50 8.5 (IC50 3x10-9 M) [9]
milrinone Hs Inhibition 7.3 pIC50
pIC50 7.3 (IC50 4.91x10-8 M)
SCH51866 Hs Inhibition 7.2 pIC50 12
pIC50 7.2 (IC50 6.31x10-8 M) [12]
zaprinast Hs Inhibition 6.8 pIC50 11
pIC50 6.8 (IC50 1.58x10-7 M) [11]
ibudilast Hs Inhibition 4.0 pIC50 2
pIC50 4.0 (IC50 1.03x10-4 M) [2]
nitrosoprodenafil Hs Inhibition - - 13
[13]
Inhibitor Comments
Tadalafil is selective for PDE5A over other PDEs tested [9]. Vardenafil is also selective for PDE5A, the next closest inhibitory effect is on PDE3 (IC50 1nM) [3].
Immunopharmacology Comments
The role of PDE5A in immuno-oncology is reviewed in [1].
Immuno Process Associations
Immuno Process:  T cell (activation)
GO Annotations:  Associated to 1 GO processes, IEA only
click arrow to show/hide IEA associations
GO:0042130 negative regulation of T cell proliferation IEA
Immuno Process:  Immune regulation
GO Annotations:  Associated to 1 GO processes, IEA only
click arrow to show/hide IEA associations
GO:0042130 negative regulation of T cell proliferation IEA
Immuno Process:  Chemotaxis & migration
GO Annotations:  Associated to 1 GO processes, IEA only
click arrow to show/hide IEA associations
GO:0042130 negative regulation of T cell proliferation IEA
Immuno Process:  Cellular signalling
GO Annotations:  Associated to 1 GO processes, IEA only
click arrow to show/hide IEA associations
GO:0042130 negative regulation of T cell proliferation IEA
General Comments
PDE5 is the main cGMP-metabolizing enzyme. Three major PDE5 isoforms are described (A1, A2 and A3). PDE5 is highly expressed in vascular and bronchial smooth muscle, in renal tubules and in platelets. Clinically used PDE5 inhibitors target PDE5 in vascular muscle (to treat erectile dysfunction) and bronchial smooth muscle (to treat pulmonary arterial hypertension). PDE5 is highly expressed in cardiac tissues of experimental and human heart disease, suggesting it as a therapeutic target for cardiovascular disease via the repurposing of existing drugs (reviewed in [7]).

References

Show »

1. Adams JL, Smothers J, Srinivasan R, Hoos A. (2015) Big opportunities for small molecules in immuno-oncology. Nat Rev Drug Discov, 14 (9): 603-22. [PMID:26228631]

2. Allcock RW, Blakli H, Jiang Z, Johnston KA, Morgan KM, Rosair GM, Iwase K, Kohno Y, Adams DR. (2011) Phosphodiesterase inhibitors. Part 1: Synthesis and structure-activity relationships of pyrazolopyridine-pyridazinone PDE inhibitors developed from ibudilast. Bioorg. Med. Chem. Lett., 21 (11): 3307-12. [PMID:21530250]

3. Boyle CD, Xu R, Asberom T, Chackalamannil S, Clader JW, Greenlee WJ, Guzik H, Hu Y, Hu Z, Lankin CM et al.. (2005) Optimization of purine based PDE1/PDE5 inhibitors to a potent and selective PDE5 inhibitor for the treatment of male ED. Bioorg. Med. Chem. Lett., 15 (9): 2365-9. [PMID:15837326]

4. Clerin V, Gale J, Tamimi N. (2014) Use of a tetrasubstituted pyrazolo[4,3-d]pyrimidine compound for treating diabetic nephropathy. Patent number: WO-2014064566-A1. Assignee: Pfizer Inc.. Priority date: 23/10/2012. Publication date: 01/05/2014.

5. Corbin JD, Turko IV, Beasley A, Francis SH. (2000) Phosphorylation of phosphodiesterase-5 by cyclic nucleotide-dependent protein kinase alters its catalytic and allosteric cGMP-binding activities. Eur. J. Biochem., 267 (9): 2760-7. [PMID:10785399]

6. Hughes RO, Walker JK, Rogier DJ, Heasley SE, Blevis-Bal RM, Benson AG, Jacobsen EJ, Cubbage JW, Fobian YM, Owen DR et al.. (2009) Optimization of the aminopyridopyrazinones class of PDE5 inhibitors: discovery of 3-[(trans-4-hydroxycyclohexyl)amino]-7-(6-methoxypyridin-3-yl)-1-(2-propoxyethyl)pyrido[3,4-b]pyrazin-2(1H)-one. Bioorg. Med. Chem. Lett., 19 (17): 5209-13. [PMID:19631533]

7. Korkmaz-Icöz S, Radovits T, Szabó G. (2018) Targeting phosphodiesterase 5 as a therapeutic option against myocardial ischaemia/reperfusion injury and for treating heart failure. Br. J. Pharmacol., 175 (2): 223-231. [PMID:28213937]

8. Mochida H, Takagi M, Inoue H, Noto T, Yano K, Fujishige K, Sasaki T, Yuasa K, Kotera J, Omori K et al.. (2002) Enzymological and pharmacological profile of T-0156, a potent and selective phosphodiesterase type 5 inhibitor. Eur. J. Pharmacol., 456 (1-3): 91-8. [PMID:12450574]

9. Mohamed HA, Girgis NM, Wilcken R, Bauer MR, Tinsley HN, Gary BD, Piazza GA, Boeckler FM, Abadi AH. (2011) Synthesis and molecular modeling of novel tetrahydro-β-carboline derivatives with phosphodiesterase 5 inhibitory and anticancer properties. J. Med. Chem., 54 (2): 495-509. [PMID:21189023]

10. Rawson DJ, Ballard S, Barber C, Barker L, Beaumont K, Bunnage M, Cole S, Corless M, Denton S, Ellis D et al.. (2012) The discovery of UK-369003, a novel PDE5 inhibitor with the potential for oral bioavailability and dose-proportional pharmacokinetics. Bioorg. Med. Chem., 20 (1): 498-509. [PMID:22100260]

11. Turko IV, Ballard SA, Francis SH, Corbin JD. (1999) Inhibition of cyclic GMP-binding cyclic GMP-specific phosphodiesterase (Type 5) by sildenafil and related compounds. Mol. Pharmacol., 56 (1): 124-30. [PMID:10385692]

12. Vemulapalli S, Watkins RW, Chintala M, Davis H, Ahn HS, Fawzi A, Tulshian D, Chiu P, Chatterjee M, Lin CC et al.. (1996) Antiplatelet and antiproliferative effects of SCH 51866, a novel type 1 and type 5 phosphodiesterase inhibitor. J. Cardiovasc. Pharmacol., 28 (6): 862-9. [PMID:8961086]

13. Venhuis BJ, Zomer G, Hamzink M, Meiring HD, Aubin Y, de Kaste D. (2011) The identification of a nitrosated prodrug of the PDE-5 inhibitor aildenafil in a dietary supplement: a Viagra with a pop. J Pharm Biomed Anal, 54 (4): 735-41. [PMID:21145686]

14. Wang G, Liu Z, Chen T, Wang Z, Yang H, Zheng M, Ren J, Tian G, Yang X, Li L et al.. (2012) Design, synthesis, and pharmacological evaluation of monocyclic pyrimidinones as novel inhibitors of PDE5. J. Med. Chem., 55 (23): 10540-50. [PMID:23137303]

How to cite this page

Phosphodiesterases, 3',5'-cyclic nucleotide (PDEs): phosphodiesterase 5A. Last modified on 18/01/2018. Accessed on 17/07/2018. IUPHAR/BPS Guide to PHARMACOLOGY, http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1304.